Actuate Therapeutics Inc (ACTU) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 5.71M | 4.69M | 5.47M | 5.97M | 6.37M | 6.56M | 5.39M | 5.44M | 7.77M | 7.62M | 5.3M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.14M | 2.56M | 3.29M | 3.2M | 3.15M | 2.87M | 1.64M | 1.06M | 912.82K | 969.35K | 774.8K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 2.57M | 2.13M | 2.18M | 2.76M | 3.22M | 3.69M | 3.76M | 4.37M | 6.86M | 6.65M | 4.52M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -5.71M | -4.69M | -5.47M | -5.97M | -6.37M | -6.56M | -5.39M | -5.44M | -7.77M | -7.62M | -5.3M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 10.36% | 28.53% | -1.47% | -9.81% | 18.11% | 13.87% | - | - | - | - | - |
| EBITDA | -5.71M | -4.69M | -5.4M | -5.94M | -6.31M | -6.44M | -5.97M | -6.57M | -8.29M | -7.61M | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 9.6% | 27.22% | 9.47% | 9.48% | 23.87% | 15.33% | - | - | - | - | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 118.11K | 0 | 0 | 0 | 8.09K | 5.3M |
| EBIT | -5.71M | -4.69M | -5.4M | -5.94M | -6.31M | -6.44M | -5.97M | -6.57M | -8.29M | -7.61M | -5.3M |
| Net Interest Income | 80.21K | 134.52K | 64.91K | 19.47K | 48.56K | 113.04K | 77.26K | 3.57K | 9.71K | 54.63K | 23.2K |
| Interest Income | 85.27K | 139.58K | 69.97K | 24.53K | 53.62K | 118.11K | 80.75K | 8.64K | 14.79K | 59.69K | 23.2K |
| Interest Expense | 5.06K | 5.06K | 5.06K | 5.06K | 5.06K | 5.08K | 3.49K | 5.08K | 5.08K | 5.06K | 0 |
| Other Income/Expense | 80.21K | 134.52K | 64.91K | 19.47K | 48.56K | 113.04K | -578.06K | -1.14M | -522.8K | 3.03K | 28.3K |
| Pretax Income | -5.63M | -4.55M | -5.41M | -5.95M | -6.32M | -6.45M | -5.97M | -6.57M | -8.3M | -7.61M | -5.27M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 800 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | -0.02% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -5.63M | -4.55M | -5.41M | -5.95M | -6.32M | -6.45M | -5.97M | -6.57M | -8.3M | -7.61M | -5.27M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 10.94% | 29.35% | 9.44% | 9.48% | 23.86% | 15.32% | - | - | - | - | - |
| Net Income (Continuing) | -5.63M | -4.55M | -5.41M | -5.95M | -6.32M | -6.45M | -5.97M | -6.57M | -8.3M | -7.61M | -5.27M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.24 | -0.20 | -0.25 | -0.30 | -0.32 | -0.60 | -0.55 | -0.34 | -0.54 | -0.50 | -0.39 |
| EPS Growth % | 25% | 66.67% | 54.55% | 11.76% | 40.74% | -20% | - | - | - | - | - |
| EPS (Basic) | -0.24 | -0.20 | -0.25 | -0.30 | -0.32 | -0.60 | -0.55 | -0.34 | -0.54 | -0.50 | -0.39 |
| Diluted Shares Outstanding | 23.54M | 23.25M | 21.39M | 19.65M | 19.5M | 19.51M | 19.51M | 19.53M | 15.49M | 15.26M | 13.4M |
| Basic Shares Outstanding | 23.54M | 23.25M | 21.39M | 19.65M | 19.5M | 19.51M | 19.51M | 19.53M | 15.49M | 15.26M | 13.39M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |